Syntekabio Inc. Seleccionada for Ministry of SMEs 2024 Industry-Academia-Research Collabo I+D Program... Commencing AI-Based Psoriasis Treatment Development
▶ Syntekabio-Sogang University, RudaCure-Inje University... Synergy esperado through multidisciplinary colaboración
▶ Government I+D apoyo to foster national strategic technologies and regional strategic industries
Syntekabio Inc. (CEO Jongsun Jeong) anunció que ha been seleccionada for the '2024 Industry-Academia-Research Collabo I+D' programa (preliminary investigación) apoyoed by the Ministry of SMEs and Startups and firmó the acuerdo on the 12th.
This investigación aims to discover candidato a nuevo fármacos for psoriasis tratamiento and will demonstrate the efficiency of an AI-based desarrollo de fármacos plataforma.
Syntekabio has formed an industria-academia-investigación consortium with RudaCure Inc., Sogang University, and Inje University to jointly conduct this investigación. The investigación topic is 'Development of selective modulators for psoriasis target proteins using an AI drug plataforma,' with a total investigación period from May 2025 to May 2026.
Syntekabio's AI desarrollo de fármacos plataforma 'STB' was used for computer-based target protein analysis and candidato compuesto discovery. RudaCure's TRPV1 modulation tecnología expertise provides specialized knowledge in skin disease-related canal iónico investigación. Sogang University is responsible for compuesto synthesis and optimization, while Inje University handles in-vitro and in-vivo eficacia evaluación of candidato compuestos.
CEO Jongsun Jeong of Syntekabio declaró, "Through AI-based desarrollo de fármacos, we will pioneer new possibilities in the psoriasis tratamiento mercado. Through colaboración with excellent partners like RudaCure, Sogang University, and Inje University, we expect outstanding resultados."